Page 87 - 《中国药科大学学报》2026年第2期

第 57 卷第 2 期 乔佳男，等：胰腺癌靶向纳米载体的合成、表征及其改善光动力治疗研究 213
A ZnPc Hoechst 33342 Bright field Merge B Control

300 ZnPc
LL/ZnPc
Free ZnPc 200 PTP+LL-PTP/ZnPc
Count LL-PTP/ZnPc
100

LL/ZnPc 0 10 1 10 2 10 3 10 4 10 5
R1-A::APC-A
C ***
60 000 LL-PTP/ZnPc
PTP+LL-PTP/ZnPc
MFI of ZnPc 20 000 ZnPc
LL-PTP/ZnPc 40 000 *** LL/ZnPc
Control

0
PTP+LL-PTP/ZnPc
LL-PTP/ZnPc
PTP+LL-PTP LL/ZnPc ZnPc Control
/ZnPc

Figure 6 Effects of different groups on uptake of PANC-1 cells
A: Representative CLSM images of PANC-1 cells incubated with different formulations for 12 h (n = 3). Scale bars represent 10 μm; B: Flow
cytometry measurement of the intracellular uptake of different formulations in PANC-1 cells for 12 h; C: Comparison of mean fluorescence intensity
(MFI) of ZnPc in PANC-1 cells ( x ± s, n =3)
***P<0.001

##

A B
Control 60 000
LL/ZnPc+Laser **
120 PTP+LL-PTP/ZnPc+Laser ** **
LL-PTP/ZnPc+Laser 40 000
Count 90 MFI of DCF
60

30 20 000
0 0
10 3 10 4 10 5
ZnPc+Laser
B1-A::FITC-A Control LL/ZnPc+ Laser PTP+LL-PTP LL-PTP/ZnPc+ Laser

C 120 D 120 ns ## ## ## ## LL
100 LND 100 * ** LL/ZnPc
Cell Viability/% 60 ZnPc+Laser Cell Viability/% 60 ** LL-PTP/ZnPc+
LL/ZnPc+Laser
ZnPc
80
80
Laser
40
20
20 40 **
*
0 0
0.04 0.2 1 5 25 ZnPc 0.0016 0.008 0.04 0.2 1 ZnPc
0.035 0.17 0.86 4.32 21.6 LND 0.0014 0.0069 0.035 0.17 0.86 LND
c/(μg/mL) c/(μg/mL)
Figure 7 In vitro pharmacodynamics of LL-PTP/ZnPc+Laser
A: Flow cytometry measurement of the fluorescence intensity of DCF in PANC-1 cells after incubation with LL/ZnPc, LL-PTP/ZnPc and PTP+LL-
**
##
PTP/ZnPc with laser; B: Comparison of MFI of DCF in PANC-1 cells ( x ± s, n = 3). P<0.01 vs control; P<0.01; C: Cell survivals of PANC-1 cells
treated with LND, ZnPc and ZnPc+Laser as determined by the MTT assay. Data are represented as mean±SD (n = 6); D: Cell survivals of PANC-1
cells treated with LL, LL/ZnPc, LL/ZnPc+Laser and LL-PTP/ZnPc+Laser as determined by the MTT assay ( x ± s, n = 6)
##
*P<0.05, **P<0.01 vs LL/ZnPc+Laser; ns no significant; P<0.01 vs LL/ZnPc